AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7617869 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization-transfer measurements in patients with MS
Number of subjects: 23
Study 7617869 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 23
Study 2508190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 500 mg administered four hours prior to irradiation
Number of subjects: 44
Study 2508190 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (40 Gy to the pelvic region)
Number of subjects: 44
Study 2508190 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole combined with radiation
Number of subjects: 44
Study 2508190 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 44
Study 73353 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (0.1 mg/kg)
Number of subjects: 75
Study 73353 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.1 mg/kg)
Number of subjects: 75
Study 73353 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 31719190 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐E+O (Mechanical In-Exsufflation with Oscillations)
Number of subjects: 56
Study 31719190 — intervention group
Group type: COMPARATOR
Intervention: MI‐E (Mechanical In-Exsufflation)
Number of subjects: 56
Study 29665992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (group A)
Number of subjects: 67
Study 29665992 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone (group B)
Number of subjects: 67
Study 27604769 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal multiple micronutrient (MM) supplementation
Number of subjects: 8529
Study 27604769 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) supplementation
Number of subjects: 8529
Study 24496084 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EXE) - combined aerobic and resistance workouts, 6 days/week for 60 minutes/day
Number of subjects: 28
Study 24496084 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - maintained sedentary lifestyle
Number of subjects: 28
Study 24496084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EXE and CON)
Number of subjects: 28
Study 21106607 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 12
Study 21106607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20337772 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.3 mg/kg
Number of subjects: 573
Study 20337772 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 573
Study 20337772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 18837861 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM (manual‐based medical care model)
Number of subjects: 58
Study 18837861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 15820533 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of metyrapone
Number of subjects: 12
Study 15820533 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of cocaine
Number of subjects: 12
Study 15820533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15820533 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 12915938 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS‐pore PAGE
Number of subjects: 58
Study 12915938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 10482089 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% given at 10 PM
Number of subjects: 34
Study 10482089 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5%, twice daily
Number of subjects: 34
Study 10482089 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% given at 8 AM
Number of subjects: 34
Study 8739868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized seawater
Number of subjects: 20
Study 8739868 — intervention group
Group type: COMPARATOR
Intervention: Antiseptic-mucolytic saline
Number of subjects: 20
Study 1754859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 6 weeks (double-blind alternating treatment)
Number of subjects: 115
Study 1754859 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks (double-blind alternating treatment)
Number of subjects: 115
Study 1754859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine continued for 4 weeks (single-blind treatment)
Number of subjects: 115
Study 1754859 — intervention group
Group type: COMPARATOR
Intervention: Placebo until relapse or maximum 8 weeks (single-blind treatment)
Number of subjects: 115
Study 7102530 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (5 mg)
Number of subjects: 12
Study 7102530 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg)
Number of subjects: 12
Study 7102530 — intervention group
Group type: EXPERIMENTAL
Intervention: inhaled fenoterol (0.4 mg)
Number of subjects: 12
Study 31948000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Vibration Rolling (DVR)
Number of subjects: 20
Study 31948000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Rolling (VR)
Number of subjects: 20
Study 31948000 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 20
Study 31948000 — intervention group
Group type: COMPARATOR
Intervention: DVR compared to SS
Number of subjects: 20
Study 31948000 — intervention group
Group type: COMPARATOR
Intervention: VR compared to SS
Number of subjects: 20
Study 31948000 — intervention group
Group type: COMPARATOR
Intervention: DVR compared to VR
Number of subjects: 20
Study 31448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill group (hydrochlorothiazide 12·5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg or valsartan 40 mg)
Number of subjects: 6838
Study 31448738 — intervention group
Group type: COMPARATOR
Intervention: Minimal care group (non-pharmacological preventive interventions)
Number of subjects: 6838
Study 31448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill group (high adherence)
Number of subjects: 6838
Study 31448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill group
Number of subjects: 6838
Study 31448738 — intervention group
Group type: COMPARATOR
Intervention: Minimal care group
Number of subjects: 6838
Study 29427230 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of recent infection (≤ 6 months)
Number of subjects: 1137
Study 29427230 — intervention group
Group type: EXPERIMENTAL
Intervention: MAA classification for individuals diagnosed within 6 months (unknown duration)
Number of subjects: 1137
Study 29427230 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnosed ≥ 2 years before randomization)
Number of subjects: 1137
Study 29427230 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants recently infected by self-report and/or MAA
Number of subjects: 1137
Study 27506485 — intervention group
Group type: EXPERIMENTAL
Intervention: Overminus spectacles (-2.50 D over cycloplegic refraction)
Number of subjects: 58
Study 27506485 — intervention group
Group type: COMPARATOR
Intervention: Observation (non-overminus spectacles if needed or no spectacles)
Number of subjects: 58
Study 25052784 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 103
Study 25052784 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive-behavioral therapy (CBT)
Number of subjects: 103
Study 23225299 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact + resistance exercise (POWIR)
Number of subjects: 106
Study 23225299 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching (FLEX)
Number of subjects: 106
Study 20972656 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin zeta
Number of subjects: 481
Study 20972656 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 481
Study 18855174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling at baseline
Number of subjects: 321
Study 18855174 — intervention group
Group type: COMPARATOR
Intervention: Depression at baseline
Number of subjects: 321
Study 18855174 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 321
Study 15797312 — intervention group
Group type: EXPERIMENTAL
Intervention: Astronauts during flight
Number of subjects: 32
Study 15797312 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 32
Study 15797312 — intervention group
Group type: EXPERIMENTAL
Intervention: Astronauts (10 days before flight and on landing day)
Number of subjects: 32
Study 15797312 — intervention group
Group type: EXPERIMENTAL
Intervention: Astronauts on landing day
Number of subjects: 32
Study 15797312 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited study (n=5) on landing day
Number of subjects: 32
Study 12201922 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral interstitial laser coagulation (ILC)
Number of subjects: 118
Study 12201922 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 118
Study 12201922 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection or incision of the prostate (TUR-P/TUI-P)
Number of subjects: 118
Study 12201922 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TUMT and TUR-P/TUI-P
Number of subjects: 118
Study 10710122 — intervention group
Group type: EXPERIMENTAL
Intervention: UR-7247 2.5 mg
Number of subjects: 16
Study 10710122 — intervention group
Group type: EXPERIMENTAL
Intervention: UR-7247 5 mg
Number of subjects: 16
Study 10710122 — intervention group
Group type: EXPERIMENTAL
Intervention: UR-7247 10 mg
Number of subjects: 16
Study 10710122 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 16
Study 9015796 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg phenylalanine
Number of subjects: 18
Study 9015796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8195856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim, 200 mg once-a-day on the first day and 100 mg once-a-day on the following days
Number of subjects: 78
Study 8195856 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor, 40 mg/Kg/day in three doses
Number of subjects: 78
Study 3529357 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 12
Study 3529357 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-(1-21)-peptide
Number of subjects: 12
Study 3529357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30860547 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Number of subjects: 0
Study 30860547 — intervention group
Group type: COMPARATOR
Intervention: Intravitreous Ranibizumab
Number of subjects: 0
Study 29989185 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM-guided pacemaker implantation into RVAPS (EAM-RVAPS)
Number of subjects: 21
Study 29989185 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic-guided implantation into RV apex (RVA)
Number of subjects: 21
Study 28089902 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg plus azelnidipine 16 mg
Number of subjects: 28
Study 28089902 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg plus trichlormethiazide 1 mg
Number of subjects: 28
Study 25596097 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational guideline for aerobic exercise and stretching
Number of subjects: 34
Study 24265770 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 22
Study 24265770 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electro Stimulation (NMES)
Number of subjects: 22
Study 24265770 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 20852905 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (AEN group, n = 48)
Number of subjects: 96
Study 20852905 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (control group, n = 48)
Number of subjects: 96
Study 18339052 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate combined with vitamins C (500 mg) and B(6) (75 mg) and proline
Number of subjects: 60
Study 18339052 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 60
Study 18339052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16580765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 18
Study 12662184 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR100893 (1 mg)
Number of subjects: 139
Study 12662184 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR100893 (5 mg)
Number of subjects: 139
Study 12662184 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR100893 (20 mg)
Number of subjects: 139
Study 12662184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 11218053 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 11218053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9385040 — intervention group
Group type: EXPERIMENTAL
Intervention: KAKKONTO coadministration (group K)
Number of subjects: 0
Study 9385040 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (APAP) administration (group A)
Number of subjects: 0
Study 9385040 — intervention group
Group type: EXPERIMENTAL
Intervention: KAKKONTO at 100 mg/kg (group K) in rats
Number of subjects: 0
Study 9385040 — intervention group
Group type: EXPERIMENTAL
Intervention: KAKKONTO at two different doses
Number of subjects: 0
Study 1333097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K treatment during the last 6 weeks prior to delivery
Number of subjects: 0
Study 1333097 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 1333097 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated women
Number of subjects: 0
Study 1333097 — intervention group
Group type: COMPARATOR
Intervention: Both placebo and vitamin K groups
Number of subjects: 0
Study 31722337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 67
Study 31722337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 67
Study 31722337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31468342 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult condition (workshop plus ability to place a medical order for an interview from a consultation‐liaison service)
Number of subjects: 1173
Study 31468342 — intervention group
Group type: COMPARATOR
Intervention: Workshop only
Number of subjects: 1173
Study 31468342 — intervention group
Group type: COMPARATOR
Intervention: Apprenticeship condition (workshop plus bedside supervision)
Number of subjects: 1173
Study 31468342 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult condition
Number of subjects: 1173
Study 31468342 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 1173
Study 28641925 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g oral ManNAc
Number of subjects: 0
Study 28641925 — intervention group
Group type: EXPERIMENTAL
Intervention: 6g oral ManNAc
Number of subjects: 0
Study 28641925 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g oral ManNAc
Number of subjects: 0
Study 28641925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25537481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (300-1,200 μg bid)
Number of subjects: 58
Study 23887841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (0.6 mg/kg rt-PA plus eptifibatide 135 mcg/kg bolus and a 2-hour infusion at 0.75 mcg/kg per minute)
Number of subjects: 126
Study 23887841 — intervention group
Group type: COMPARATOR
Intervention: Standard rt-PA (0.9 mg/kg)
Number of subjects: 126
Study 23887841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 126
Study 23887841 — intervention group
Group type: COMPARATOR
Intervention: Standard rt-PA
Number of subjects: 126
Study 24303381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 60
Study 24303381 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 20609652 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128
Study 20609652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study 18219958 — intervention group
Group type: EXPERIMENTAL
Intervention: Erespall (fenspirid)
Number of subjects: 0
Study 15759215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushrim-activated power-assist wheelchair (PAPAW)
Number of subjects: 15
Study 15759215 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual wheelchair
Number of subjects: 15
Study 11941556 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine treatment
Number of subjects: 43
Study 9579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal probability level of .01
Number of subjects: 3
Study 9579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal probability level of .04
Number of subjects: 3
Study 9579106 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal probability level of .12
Number of subjects: 3
Study 8744700 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone administration
Number of subjects: 0
Study 2666707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilzem (180‐300 mg/daily)
Number of subjects: 53
Study 2666707 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinfar (30‐60 mg/daily)
Number of subjects: 53
Study 2666707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 998645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% preparation
Number of subjects: 25
Study 998645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% preparation
Number of subjects: 25
Study 998645 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.25% preparation
Number of subjects: 25
Study 998645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 998645 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.50% preparation
Number of subjects: 25
Study 998645 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.75% preparation
Number of subjects: 25
Study 998645 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.0% preparation
Number of subjects: 25
Study 31347165 — intervention group
Group type: EXPERIMENTAL
Intervention: Khorasan-based diet
Number of subjects: 20
Study 31347165 — intervention group
Group type: COMPARATOR
Intervention: Modern semi-whole-grain wheat
Number of subjects: 20
Study 30731375 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics use
Number of subjects: 39782
Study 30731375 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor NO2 and PM10, ETS, gas cooking, burning biomass, incense, and mosquito coils
Number of subjects: 39782
Study 28599898 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol 26-mL single-step applicator
Number of subjects: 932
Study 28599898 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine aqueous scrub and paint 236-mL wet skin tray
Number of subjects: 932
Study 26463012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 70
Study 26463012 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 70
Study 26463012 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 70
Study 25071065 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Checks
Number of subjects: 16669
Study 25071065 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 16669
Study 22511916 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral FTC/TDF
Number of subjects: 72
Study 22511916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral FTC/TDF (Monday, Friday and within 2 hours after sex)
Number of subjects: 72
Study 22511916 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-coital doses of FTC/TDF
Number of subjects: 72
Study 22511916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19445642 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (Group A, n = 23)
Number of subjects: 45
Study 19445642 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupuncture (Group B, n = 22)
Number of subjects: 45
Study 19445642 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (Group A)
Number of subjects: 45
Study 19445642 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupuncture (Group B)
Number of subjects: 45
Study 17264174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month structured exercise training (ET) program
Number of subjects: 90
Study 17264174 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 90
Study 14704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipse Standard Deviation (ESD)
Number of subjects: 504
Study 14704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized Superior Area (NSA)
Number of subjects: 504
Study 14704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized Inferior Area (NIA)
Number of subjects: 504
Study 14704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant Analysis (DA)
Number of subjects: 504
Study 14704540 — intervention group
Group type: COMPARATOR
Intervention: The Number (existing parameter)
Number of subjects: 504
Study 11474327 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (EX)
Number of subjects: 31
Study 9571346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (30 J/cm2)
Number of subjects: 30
Study 9571346 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 30
Study 8053584 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Number of subjects: 50